Skip to main content
ASHI 51st Annual Meeting Main banner

Richard Carvajal, MD

Professor of Medicine
Northwell Health Cancer Institute
Lake Success, NY

Richard D. Carvajal, MD, is the Roy J. and Tara Zuckerberg Professor in Medical Oncology and the Deputy Physician-in-Chief and Director of Hematology/Oncology at the Northwell Health Cancer Institute. He is recognized as a leader within the cancer drug development and melanoma fields. The multicenter, investigator-initiated clinical trials that he has developed have been practice changing, leading to the inclusion of imatinib, a multi-tyrosine kinase receptor inhibitor, in the National Comprehensive Cancer Network (NCCN) Melanoma guideline as a treatment option for patient with advanced melanoma harboring KIT alterations and the inclusion of trametinib, an allosteric inhibitor of MEK1/2, in the NCCN Uveal Melanoma guideline as a treatment option for patients with advanced disease. He has served as principal investigator of multiple international industry sponsored trials, and led the phase I/II study of tebentafusp, which was demonstrated in a randomized phase III study to meaningfully improve survival in HLA-A0201 positive patients with untreated metastatic uveal melanoma. His research has been supported by the National Cancer Institute, the Food and Drug Administration, the Conquer Cancer Foundation, the Melanoma Research Alliance, and the Melanoma Research Foundation. He has authored or co-authored more than 250 peer-reviewed manuscripts, books, and book chapters.

Presentation(s):